Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + oxaliplatin + S-1 neoadjuvant therapy for Siewert type II EGJ adenocarcinoma
ChiCTR2300075638Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in gastroesophageal junction adenocarcinoma, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Pathologic Complete Response. Started Sep 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300075638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075638.